EUVIMEDEUVIMED entdecken
Crossref

Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway

Lanmei Chen iD, Wenzhu Yu, Hong Tang, Shenting Zhang, Jie Wang, Qianqian Ouyang, Miao Guo, Xufeng Zhu, Zunnan Huang, Jincan Chen iD

Metallomics · 2024

DOI: 10.1093/mtomcs/mfae002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metallomics, 2024. Verfasst von Lanmei Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Computer-Aided Drug Design of Dongguan City, Guangdong Key Laboratory for Research and Development of Natural Drugs, School of Phar…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Ruthenium, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Discipline Construction Project of Guangdong Medical University, Science and Technology Program of Zhanjiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, cisplatin resistance remains a primary clinical obstacle in the successful treatment of non-small cell lung cancer. Here, we designed, synthesized, and characterized two novel cyclometalated Ru(II) complexes, [Ru(bpy)2(1-Ph-7-OCH3-IQ)] (PF6) (bpy = 2,2ʹ-bipyridine, IQ = isoquinoline, RuIQ7)and [Ru(bpy)2(1-Ph-6,7-(OCH3)2-IQ)] (PF6) (RuIQ8). As experimental controls, we prepared complex [Ru(bpy)2(1-Ph-IQ)](PF6) (RuIQ6) lacking a methoxy group in the main ligand. Significantly, complexes RuIQ6-8 displayed higher in vitro cytotoxicity when compared to ligands, precursor cis-[Ru(bpy)2Cl2], and clinical cisplatin. Mechanistic investigations revealed that RuIQ6-8 could inhibit cell proliferation by downregulating the phosphorylation levels of Akt and mTOR proteins, consequently affecting the rapid growth of human lung adenocarcinoma cisplatin-resistant cells A549/DDP. Moreover, the results from qRT-PCR demonstrated that these complexes could directly suppress the transcription of the NF-E2-related factor 2 gene, leading to the inhibition of downstream multidrug resistance-associated protein 1 expression and effectively overcoming cisplatin resistance. Furthermore, the relationship between the chemical structures of these three complexes and their anticancer activity, ability to induce cell apoptosis, and their efficacy in overcoming cisplatin resistance has been thoroughly examined and discussed. Notably, the toxicity test conducted on zebrafish embryos indicated that the three Ru-IQ complexes displayed favorable safety profiles. Consequently, the potential of these developed compounds as innovative therapeutic agents for the efficient and low-toxic treatment of NSCLC appears highly promising.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRutheniumLung NeoplasmsAntineoplastic AgentsCoordination ComplexesOrganometallic CompoundsAnimalsHumansCisplatinNF-E2-Related Factor 2Phosphatidylinositol 3-KinasesZebrafishSignal TransductionTOR Serine-Threonine KinasesCell Line, Tumor2,2'-Dipyridyl

Stichwörter der Autor:innen

A549/DDPPI3K/mTOR/Nrf2cisplatin resistancecyclometalated ruthenium complexes

Substanzen

Cisplatinbis(bipyridyl)ruthenium(II)RutheniumNF-E2-Related Factor 2Phosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesAntineoplastic AgentsCoordination ComplexesOrganometallic Compounds2,2'-Dipyridyl

Autor:innen und Institutionen

  • Key Laboratory of Computer-Aided Drug Design of Dongguan City, Guangdong Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong 523808, P. R.…
  • The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, Guangdong 524023, P. R. China.
  • The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, Guangdong 524023, P. R. China.

ORCID-Profile: Lanmei Chen, Jincan Chen

Förderung

  • National Natural Science Foundation of China
  • Discipline Construction Project of Guangdong Medical University
  • Science and Technology Program of Zhanjiang
  • Medical Scientific Research Foundation of Guangdong Province of China
  • Science and Technology Program of Guangdong Province
  • Ph.D. Start-up Fund of Guangdong Medical University
  • University Student Innovation Experiment Program

Zitieren

APA

Chen, L., Yu, W., Tang, H., Zhang, S., Wang, J., Ouyang, Q., Guo, M., Zhu, X., Huang, Z., & Chen, J. (2024). Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway. Metallomics. https://doi.org/10.1093/mtomcs/mfae002

Vancouver

Chen L, Yu W, Tang H, Zhang S, Wang J, Ouyang Q, et al. Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway. Metallomics. 2024. doi:10.1093/mtomcs/mfae002

BibTeX
@article{Chen2024,
  author = {Chen, Lanmei and Yu, Wenzhu and Tang, Hong and Zhang, Shenting and Wang, Jie and Ouyang, Qianqian and Guo, Miao and Zhu, Xufeng and Huang, Zunnan and Chen, Jincan},
  title = {Cyclometalated ruthenium complexes overcome cisplatin resistance through PI3K/mTOR/Nrf2 signaling pathway},
  journal = {Metallomics},
  year = {2024},
  doi = {10.1093/mtomcs/mfae002}
}
Kostenlos starten →